Trending Stock News

Veru Inc. (VERU) Analysts See $-0.02 EPS; Swiss National Bank Cut Its Cintas (CTAS) Stake

Cintas Corporation (NASDAQ:CTAS) Logo

Swiss National Bank decreased Cintas Corp (CTAS) stake by 16.73% reported in 2017Q4 SEC filing. Swiss National Bank sold 80,600 shares as Cintas Corp (CTAS)’s stock rose 8.12%. The Swiss National Bank holds 401,248 shares with $62.53 million value, down from 481,848 last quarter. Cintas Corp now has $18.49B valuation. The stock decreased 0.65% or $1.13 during the last trading session, reaching $173.25. About 115,927 shares traded. Cintas Corporation (NASDAQ:CTAS) has risen 35.54% since April 19, 2017 and is uptrending. It has outperformed by 23.99% the S&P500.

Analysts expect Veru Inc. (NASDAQ:VERU) to report $-0.02 EPS on May, 8.They anticipate $0.04 EPS change or 66.67% from last quarter’s $-0.06 EPS. After having $-0.03 EPS previously, Veru Inc.’s analysts see -33.33% EPS growth. The stock decreased 1.12% or $0.02 during the last trading session, reaching $1.77. About 39,796 shares traded. Veru Inc. (NASDAQ:VERU) has risen 64.49% since April 19, 2017 and is uptrending. It has outperformed by 52.94% the S&P500.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products. The company has market cap of $94.72 million. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It currently has negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

Swiss National Bank increased Square Inc stake by 563,700 shares to 929,100 valued at $32.21M in 2017Q4. It also upped Waste Mgmt Inc Del (NYSE:WM) stake by 28,100 shares and now owns 2.47M shares. Westar Energy Inc (NYSE:WR) was raised too.

Since January 12, 2018, it had 0 insider buys, and 1 insider sale for $1.99 million activity. 12,386 Cintas Corporation (NASDAQ:CTAS) shares with value of $1.99M were sold by Holloman James Phillip.

Analysts await Cintas Corporation (NASDAQ:CTAS) to report earnings on July, 19. They expect $1.65 earnings per share, up 39.83% or $0.47 from last year’s $1.18 per share. CTAS’s profit will be $176.09M for 26.25 P/E if the $1.65 EPS becomes a reality. After $1.37 actual earnings per share reported by Cintas Corporation for the previous quarter, Wall Street now forecasts 20.44% EPS growth.

Among 17 analysts covering Cintas (NASDAQ:CTAS), 7 have Buy rating, 2 Sell and 8 Hold. Therefore 41% are positive. Cintas had 48 analyst reports since August 14, 2015 according to SRatingsIntel. The company was initiated on Tuesday, March 27 by Goldman Sachs. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, September 27 report. Stifel Nicolaus maintained Cintas Corporation (NASDAQ:CTAS) on Friday, September 1 with “Hold” rating. Nomura downgraded the shares of CTAS in report on Tuesday, June 27 to “Hold” rating. The firm has “Buy” rating given on Tuesday, October 31 by Robert W. Baird. The firm has “Equal-Weight” rating given on Friday, August 14 by Morgan Stanley. The firm has “Neutral” rating by Instinet given on Tuesday, June 27. The stock of Cintas Corporation (NASDAQ:CTAS) earned “Buy” rating by Robert W. Baird on Thursday, January 25. As per Thursday, September 28, the company rating was maintained by RBC Capital Markets. Morgan Stanley maintained the shares of CTAS in report on Wednesday, August 17 with “Underweight” rating.

Investors sentiment decreased to 0.93 in Q4 2017. Its down 0.09, from 1.02 in 2017Q3. It is negative, as 39 investors sold CTAS shares while 185 reduced holdings. 68 funds opened positions while 141 raised stakes. 68.29 million shares or 1.49% less from 69.32 million shares in 2017Q3 were reported. Texas Permanent School Fund reported 23,507 shares. Huntington Natl Bank invested 0.01% of its portfolio in Cintas Corporation (NASDAQ:CTAS). Private Ocean Lc has invested 0% of its portfolio in Cintas Corporation (NASDAQ:CTAS). Riverhead Cap Management Limited Company invested 0.07% of its portfolio in Cintas Corporation (NASDAQ:CTAS). Cubist Systematic Strategies Ltd Liability Com invested 0.12% in Cintas Corporation (NASDAQ:CTAS). The Hong Kong-based Point72 Asia (Hong Kong) has invested 0.03% in Cintas Corporation (NASDAQ:CTAS). Pub Sector Pension Investment Board owns 4,593 shares. Fort Washington Advsr Oh has invested 2.51% in Cintas Corporation (NASDAQ:CTAS). Gotham Asset Management Limited Liability reported 0.06% stake. Ontario Teachers Pension Plan Board owns 0.09% invested in Cintas Corporation (NASDAQ:CTAS) for 49,334 shares. State Of Tennessee Treasury Department owns 119,136 shares or 0.08% of their US portfolio. Toth Fin Advisory Corporation holds 0.02% or 435 shares. Laffer Invests holds 13,165 shares or 0.51% of its portfolio. Fifth Third Natl Bank reported 104,004 shares. Rafferty Asset Mngmt Ltd Limited Liability Company has 0.03% invested in Cintas Corporation (NASDAQ:CTAS) for 9,321 shares.

Cintas Corporation (NASDAQ:CTAS) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *